Therapy Trends KOL Insight: Epilepsy
Why, despite regulatory setbacks, do KOLs consider Zogenix's Fintepla to be highly promising for Dravet syndrome? How do KOLs think safety concerns could be addressed with SK Life Science/Arvelle Therapeutics' Xcopri? Why do experts say Greenwich Biosciences/GW Pharmaceuticals' Epidiolex/Epidyolex needs to demonstrate utility beyond Dravet Syndrome and LGS to achieve substantial growth? US and European KOLs critically assess the prospects of launched and pipeline therapies.
|Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.|
Key questions answered
- What is limiting uptake of advanced sodium channel blockers such as Sunovion/BIAL/Eisai's Aptiom/Zebinix and UCB's Vimpat?
- Will UCB's Nayzilam and Neurelis' Valtoco intranasally administered therapies shape future treatment and how could Aquestive Therapeutics' buccally administered Libervant fit in?
- Why do KOLs consider Marinus Pharmaceuticals' ganaxolone to be an attractive candidate for the treatment of refractory status epilepticus?
- What lessons do KOLs have for Eisai as the use of their broad-spectrum AED drug Fycompa expands?
Examples of Therapies Covered
Partial List of Participating KOLs
|We engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.|
|Our-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.|
|Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.|
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.